These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 16299245)

  • 1. Inhibition of the met receptor in mesothelioma.
    Mukohara T; Civiello G; Davis IJ; Taffaro ML; Christensen J; Fisher DE; Johnson BE; Jänne PA
    Clin Cancer Res; 2005 Nov; 11(22):8122-30. PubMed ID: 16299245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
    Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
    Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
    Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
    Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
    Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
    Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
    Xu H; Washington S; Verderame MF; Manni A
    Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
    Ma PC; Schaefer E; Christensen JG; Salgia R
    Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide.
    Tam EM; Runyon ST; Santell L; Quan C; Yao X; Kirchhofer D; Skelton NJ; Lazarus RA
    J Mol Biol; 2009 Jan; 385(1):79-90. PubMed ID: 18973760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
    Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R
    Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
    Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
    Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
    J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Met is a potentially new therapeutic target for treatment of human melanoma.
    Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
    Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.
    Watanabe T; Tsuda M; Makino Y; Ichihara S; Sawa H; Minami A; Mochizuki N; Nagashima K; Tanaka S
    Mol Cancer Res; 2006 Jul; 4(7):499-510. PubMed ID: 16849525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
    Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.
    Suzuki Y; Sakai K; Ueki J; Xu Q; Nakamura T; Shimada H; Nakamura T; Matsumoto K
    Int J Cancer; 2010 Oct; 127(8):1948-57. PubMed ID: 20104519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness.
    Hecht M; Schulte JH; Eggert A; Wilting J; Schweigerer L
    Carcinogenesis; 2005 Dec; 26(12):2105-15. PubMed ID: 16051641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met.
    Onimaru Y; Tsukasaki K; Murata K; Imaizumi Y; Choi YL; Hasegawa H; Sugahara K; Yamada Y; Hayashi T; Nakashima M; Taguchi T; Mano H; Kamihira S; Tomonaga M
    Int J Oncol; 2008 Oct; 33(4):697-703. PubMed ID: 18813782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion.
    Murai M; Shen X; Huang L; Carpenter WM; Lin CS; Silverman S; Regezi J; Kramer RH
    Int J Oncol; 2004 Oct; 25(4):831-40. PubMed ID: 15375530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.